Huadong Medicine: Sino-US Huadong Micafungin Sodium for Injection Approved for Listing

On June 18, Huadong Medicine announced that, recently, the company’s wholly-owned subsidiary Sino-American Huadong received the "Drug Registration Certificate" for Micafungin Sodium for Injection (50mg) approved and issued by the State Food and Drug Administration
.

Micafungin sodium is the first-line drug recommended by the Infectious Diseases Society of America (IDSA) Candidiasis Clinical Practice Guidelines (2016 Edition), and is the second echinocandin antifungal drug approved for marketing in the world after caspofungin It can be used in all aspects of invasive fungal infections in patients with hematological diseases/malignant tumors, and can be applied to large-scale fungal infections that occur in ICU rescue
.

Up to now, in addition to the original research company, a total of six domestic companies (including East China, the US and China) have obtained the registration certificate of micafungin sodium
.

As of the date of this announcement, the company's cumulative direct R&D investment in micafungin sodium for injection is approximately RMB 38.